Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0003315,
umls-concept:C0021756,
umls-concept:C0024264,
umls-concept:C0039215,
umls-concept:C0108779,
umls-concept:C0150312,
umls-concept:C0205228,
umls-concept:C0439859,
umls-concept:C0871261,
umls-concept:C1510986,
umls-concept:C1516213,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2700400,
umls-concept:C2911692
|
pubmed:issue |
4
|
pubmed:dateCreated |
1990-1-30
|
pubmed:abstractText |
To see whether cancer patients possess CD3+ CD4+ lymphocytes able to proliferate in response to autologous tumor cells (Auto-Tu), this lymphocyte subset was isolated either by positive or negative selection, both methods resulting in highly enriched CD4+ populations. Unseparated and isolated CD3+ CD4+ lymphocytes were then assayed for proliferating activity in the presence or absence of various amounts of Auto-Tu, with or without recombinant interleukin-2 (IL-2) (1.5-15 U/ml) and DR+ adherent cells or E- lymphocytes as autologous accessory cells (Auto-AC). Isolated CD3+ CD4+ lymphocytes were stimulated by Auto-Tu alone in only 1 out of 12 cases. CD3+ CD4+ cells failed to proliferate significantly in response to low doses of IL-2 alone but the addition of Auto-Tu caused stimulation in 8 out of 12 cases (67%). The further addition of Auto-AC to Auto-Tu + IL-2 resulted in enhanced response of isolated CD3+ CD4+ lymphocytes in 6 out of 8 cases tested. When reactivities to Auto-Tu in the presence of IL-2 and IL-2 + Auto-AC were considered together, positive responses of CD3+ CD4+ lymphocytes were seen in 11 out of 12 cases (92%). On the other hand, unseparated lymphocytes were stimulated by Auto-Tu alone in none out of 12 cases. Unseparated lymphocytes, however, responded to IL-2 in 11 out of 12 cases; such a response was increased by the addition of Auto-Tu in only 2 cases. Moreover, the IL-2 proliferation of unseparated lymphocytes was suppressed in 4 and in 3 out of 12 cases tested when Auto-Tu or Auto-Tu + Auto-AC were added respectively. These data indicate that lymphocytes of cancer patients contain CD3+ CD4+ cells that are usually unable to proliferate in response to Auto-Tu only. This proliferation, however, occurs when low doses of exogenous IL-2 are present and can be further amplified by the addition of Auto-AC. No response of CD4+ cells is observed in the presence of DR+ Auto-AC + IL-2 except in 2 out of 7 cases tested (28%), suggesting an Auto-Tu-restricted reactivity of CD3+ CD4+ lymphocytes in the majority of cases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD3,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD4,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Antigen, T-Cell
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0340-7004
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
233-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2574630-Antigen-Presenting Cells,
pubmed-meshheading:2574630-Antigens, CD,
pubmed-meshheading:2574630-Antigens, CD3,
pubmed-meshheading:2574630-Antigens, CD4,
pubmed-meshheading:2574630-Antigens, Differentiation, T-Lymphocyte,
pubmed-meshheading:2574630-CD4-Positive T-Lymphocytes,
pubmed-meshheading:2574630-Humans,
pubmed-meshheading:2574630-Interleukin-2,
pubmed-meshheading:2574630-Lymphocyte Activation,
pubmed-meshheading:2574630-Neoplasms,
pubmed-meshheading:2574630-Phenotype,
pubmed-meshheading:2574630-Receptors, Antigen, T-Cell,
pubmed-meshheading:2574630-T-Lymphocytes
|
pubmed:year |
1989
|
pubmed:articleTitle |
Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.
|
pubmed:affiliation |
Division of Experimental Oncology D, Instituto Nazionale Tumori, Milan, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|